$HOWL
Werewolf Therapeutics, Inc. Stock $howl

$howl Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000178553023000009 Filed on March 23, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$4.464M	$7.283M	$16.40M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.981M	$4.603M	$18.70M
YoY Change	12.67%	2.65%	26.17%
% of Gross Profit
Research & Development	$11.71M	$15.86M	$53.76M
YoY Change	6.95%	18.35%	52.43%
% of Gross Profit
Depreciation & Amortization	$425.0K	$417.0K	$1.100M
YoY Change	333.67%	768.75%	409.26%
% of Gross Profit
Operating Expenses	$16.69M	$20.46M	$72.46M
YoY Change	8.6%	14.42%	44.66%
Operating Profit	-$12.22M		-$56.06M
YoY Change	-20.45%		11.92%
Interest Expense	$1.347M	$1.179M	$1.908M
YoY Change	5756.52%	7760.0%	1734.62%
% of Operating Profit
Other Income/Expense, Net	$241.0K	$70.00K	$2.246M
YoY Change	947.83%		2059.62%
Pretax Income	-$11.98M	-$11.93M	-$53.81M
YoY Change	-21.91%	-33.24%	7.66%
Income Tax
% Of Pretax Income
Net Earnings	-$11.98M	-$11.93M	-$53.81M
YoY Change	-21.91%	-33.24%	7.66%
Net Earnings / Revenue	-268.41%	-163.81%	-328.09%
Basic Earnings Per Share	-$0.34		-$1.86
Diluted Earnings Per Share	-$0.34	-$0.39	-$1.86
COMMON SHARES
Basic Shares Outstanding	35.28M shares	30.74M shares	28.86M shares
Diluted Shares Outstanding	34.79M shares		28.86M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$147.9M	$129.3M	$129.3M
YoY Change	2.89%	-17.91%	-17.91%
Cash & Equivalents	$147.9M	$129.3M	$129.3M
Short-Term Investments
Other Short-Term Assets	$2.439M	$3.957M	$3.957M
YoY Change	41.39%	11.87%	11.87%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$6.255M	$6.928M
Total Short-Term Assets	$156.6M	$140.2M	$140.2M
YoY Change	7.65%	-12.96%	-12.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.699M	$8.988M	$17.45M
YoY Change	41.65%	208.55%	6.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$670.0K	$1.380M	$2.594M
YoY Change	4.36%	112.63%	39.69%
Total Long-Term Assets	$38.51M	$20.05M	$20.05M
YoY Change	100.61%	10.25%	10.25%
TOTAL ASSETS
Total Short-Term Assets	$156.6M	$140.2M	$140.2M
Total Long-Term Assets	$38.51M	$20.05M	$20.05M
Total Assets	$195.1M	$160.2M	$160.2M
YoY Change	18.49%	-10.6%	-10.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.106M	$1.221M	$1.221M
YoY Change	52.5%	-40.06%	-40.06%
Accrued Expenses	$13.32M	$14.15M	$16.24M
YoY Change	62.67%	61.46%	65.05%
Deferred Revenue		$6.500M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.72M	$23.99M	$23.99M
YoY Change	96.97%	102.03%	102.03%
LONG-TERM LIABILITIES
Long-Term Debt	$39.06M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$191.0K	$13.92M
YoY Change	-100.0%		-4.59%
Total Long-Term Liabilities	$0.00	$191.0K	$13.92M
YoY Change	-100.0%		-4.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.72M	$23.99M	$23.99M
Total Long-Term Liabilities	$0.00	$191.0K	$13.92M
Total Liabilities	$74.00M	$37.91M	$37.91M
YoY Change	192.32%	43.25%	43.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$318.7M	-$306.7M
YoY Change	18.81%	21.28%
Common Stock	$3.000K	$3.000K
YoY Change	50.0%	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$121.1M	$122.3M	$122.3M
YoY Change
Total Liabilities & Shareholders Equity	$195.1M	$160.2M	$160.2M
YoY Change	18.49%	-10.6%	-10.6%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$11.98M	-$11.93M	-$53.81M
YoY Change	-21.91%	-33.24%	7.66%
Depreciation, Depletion And Amortization	$425.0K	$417.0K	$1.100M
YoY Change	333.67%	768.75%	409.26%
Cash From Operating Activities	-$9.898M	-$11.87M	-$40.60M
YoY Change	-29.05%	-6.34%	-5.32%
INVESTING ACTIVITIES
Capital Expenditures	$168.0K	$518.0K	$3.611M
YoY Change	500.0%	-290.44%	625.1%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$168.0K	-$518.0K	-$3.611M
YoY Change	500.0%	90.44%	625.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$16.19M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$48.62M	1.256M	$15.91M
YoY Change	30480.5%	3205.26%	-85.46%
NET CHANGE
Cash From Operating Activities	-$9.898M	-11.87M	-$40.60M
Cash From Investing Activities	-$168.0K	-518.0K	-$3.611M
Cash From Financing Activities	$48.62M	1.256M	$15.91M
Net Change In Cash	$38.56M	-11.13M	-$28.30M
YoY Change	-378.99%	-13.75%	-142.85%
FREE CASH FLOW
Cash From Operating Activities	-$9.898M	-$11.87M	-$40.60M
Capital Expenditures	$168.0K	$518.0K	$3.611M
Free Cash Flow	-$10.07M	-$12.39M	-$44.21M
YoY Change	-27.99%	-0.1%	1.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001785530
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	59285867	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35279820	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129315000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	157531000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-252895000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	122337000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	152787000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3957000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3537000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	6928000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	140200000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	161068000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8988000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2913000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1214000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1208000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8463000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13412000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1380000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	649000	usd
CY2022Q4	us-gaap	Assets Assets	160245000	usd
CY2021Q4	us-gaap	Assets Assets	179250000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1221000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2037000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14152000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8765000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2084000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1072000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6532000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23989000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11874000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12600000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14589000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1128000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	191000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Liabilities Liabilities	37908000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	26463000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31515000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27608000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31434000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27313000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	160245000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	179250000	usd
CY2022	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	16401000	usd
CY2021	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	429039000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	405680000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-306705000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35269000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-56056000	usd
CY2022	howl	Increase Decrease In Fair Value Of Temporary Equity Liability IncreaseDecreaseInFairValueOfTemporaryEquityLiability	338000	usd
CY2021	howl	Increase Decrease In Fair Value Of Temporary Equity Liability IncreaseDecreaseInFairValueOfTemporaryEquityLiability	0	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	1908000	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	104000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2246000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	104000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-53810000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-49983000	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	151942000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-53810000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-53810000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-201925000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-201925000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.86
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.86
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.94
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.94
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28864000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28864000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18455000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18455000	shares
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2379000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	109221000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	151942000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	293024000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4095000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	235000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-49983000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	152787000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	455000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15736000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7400000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	224000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-53810000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	122337000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7400000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	4095000	usd
CY2022	us-gaap	Depreciation Depreciation	1104000	usd
CY2021	us-gaap	Depreciation Depreciation	216000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1406000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	519000	usd
CY2022	howl	Change In Fair Value Of Success Payment Liability ChangeInFairValueOfSuccessPaymentLiability	555000	usd
CY2021	howl	Change In Fair Value Of Success Payment Liability ChangeInFairValueOfSuccessPaymentLiability	0	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	203000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-7000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	541000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3072000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	6928000	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-279000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	649000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-883000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1007000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3738000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5263000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7660000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2022	howl	Increase Decrease In Operating Lease Liability And Right Of Use Asset IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset	-977000	usd
CY2021	howl	Increase Decrease In Operating Lease Liability And Right Of Use Asset IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset	-241000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	191000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-31000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40596000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42876000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3611000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	498000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3611000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-498000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16191000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	111600000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	451000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2378000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	88000	usd
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	254000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	205000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15906000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	109427000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-28301000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	66053000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158830000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92777000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130529000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158830000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1806000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1035000	usd
CY2022	howl	Stock Option Exercise Receivables In Prepaid Expenses And Other Current Assets StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets	0	usd
CY2021	howl	Stock Option Exercise Receivables In Prepaid Expenses And Other Current Assets StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets	30000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	111000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	79000	usd
CY2022	howl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	4000	usd
CY2021	howl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13658000	usd
CY2022	us-gaap	Accretion Expense AccretionExpense	0	usd
CY2021	us-gaap	Accretion Expense AccretionExpense	151942000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1299000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1214000	usd
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	207000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1299000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158830000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129300000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, estimates related to the application of Revenue from Contracts with Customers (Topic 606) (“ASC 606”) to the Company’s collaboration agreement with Jazz Pharmaceuticals Ireland Limited, the accrual of research and development expenses, the expected future lives of property and equipment, the valuation of stock-based awards, and the success based fee associated with the Company’s debt agreement. Actual results could differ from those estimates.</span></div>
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit Risk and Off-Balance Sheet RiskFinancial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents. Cash is held in a checking account at two financial institutions. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.
CY2022Q4	howl	Concentrations Of Credit Risk Number Of Financial Institutions ConcentrationsOfCreditRiskNumberOfFinancialInstitutions	2	institution
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6500000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1100000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2022	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	15000000	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	7340000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	7660000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2022	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	15000000	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	7340000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	7660000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1200000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	1300000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129315000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92570000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	157531000	usd
CY2022Q4	howl	Success Payment Liability SuccessPaymentLiability	570000	usd
CY2021Q4	howl	Success Payment Liability SuccessPaymentLiability	0	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	170000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	163000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10394000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3304000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	1406000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	391000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	8988000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2913000	usd
CY2022	us-gaap	Depreciation Depreciation	1100000	usd
CY2021	us-gaap	Depreciation Depreciation	200000	usd
CY2021Q4	howl	Accrued Manufacturing Current AccruedManufacturingCurrent	3427000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2200000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	433000	usd
CY2022Q4	howl	Accrued Contract Research Current AccruedContractResearchCurrent	2990000	usd
CY2021Q4	howl	Accrued Contract Research Current AccruedContractResearchCurrent	2542000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14152000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8765000	usd
CY2022Q2	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.045
CY2022Q4	howl	Debt Instrument Conditional Fee Liability DebtInstrumentConditionalFeeLiability	1100000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	usd
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6565000	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5264000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7400000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4095000	usd
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.081
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	18300000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2537000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1312000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	837000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	398000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	228000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	411000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	834000	usd
CY2022	us-gaap	Lease Cost LeaseCost	2768000	usd
CY2021	us-gaap	Lease Cost LeaseCost	2121000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.081
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3133000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2505000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2337000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2403000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2472000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6258000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	19108000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4424000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	14684000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.083
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.057
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.304
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.272
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.024
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.018
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.009
CY2022	howl	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.002
CY2021	howl	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.004
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26234000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22831000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3819000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1918000	usd
CY2022Q4	howl	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	4180000	usd
CY2021Q4	howl	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	4393000	usd
CY2022Q4	howl	Deferred Tax Assets Capitalized Costs Net Of Amortization DeferredTaxAssetsCapitalizedCostsNetOfAmortization	103000	usd
CY2021Q4	howl	Deferred Tax Assets Capitalized Costs Net Of Amortization DeferredTaxAssetsCapitalizedCostsNetOfAmortization	111000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	950000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	658000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1448000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	9474000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	46208000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30411000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42417000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26110000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3791000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4301000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2358000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	3762000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1433000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6000	usd
CY2022Q4	howl	Deferred Tax Liabilities Construction In Progress DeferredTaxLiabilitiesConstructionInProgress	0	usd
CY2021Q4	howl	Deferred Tax Liabilities Construction In Progress DeferredTaxLiabilitiesConstructionInProgress	533000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3791000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4301000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	howl	Capitalized Research And Experimentation Expenses CapitalizedResearchAndExperimentationExpenses	36100000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	16300000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14300000	usd
CY2022Q4	howl	Operating Loss Carryforwards Not Subject To Expiration OperatingLossCarryforwardsNotSubjectToExpiration	92000000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	800000	usd
CY2022Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	200000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5707000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3620000	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001785530-23-000009-index-headers.html	Edgar Link	pending
0001785530-23-000009-index.html	Edgar Link	pending
0001785530-23-000009.txt	Edgar Link	pending
0001785530-23-000009-xbrl.zip	Edgar Link	pending
a12312022ex231.htm	Edgar Link	pending
a12312022ex232.htm	Edgar Link	pending
a12312022ex311.htm	Edgar Link	pending
a12312022ex312.htm	Edgar Link	pending
a12312022ex321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
howl-20221231.htm	Edgar Link	pending
howl-20221231.xsd	Edgar Link	pending
howl-20221231_g1.jpg	Edgar Link	pending
howl-20221231_g2.jpg	Edgar Link	pending
howl-20221231_g3.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
howl-20221231_pre.xml	Edgar Link	unprocessable
howl-20221231_lab.xml	Edgar Link	unprocessable
howl-20221231_htm.xml	Edgar Link	completed
howl-20221231_cal.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
howl-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HOWL
Werewolf Therapeutics, Inc. Stock $howl

2023 Q1 Form 10-K Financial Statement

#000178553023000009 Filed on March 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOWL Werewolf Therapeutics, Inc. Stock $howl

2023 Q1 Form 10-K Financial Statement

#000178553023000009 Filed on March 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOWL
Werewolf Therapeutics, Inc. Stock $howl